Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with l‐Deprenyl

Journal of Neurochemistry

Volumn 46, Issue 5, 1986, Pages 1359-1365

  Riederer, Peter ^a   Youdim, Moussa B H ^b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

5 Hydroxyindoleacetic acid; 5 Hydroxytryptamine; AGN 1135 3,4 Dihydroxyphenylethylamine; Human brain monoamine oxidase; l Deprenyl; Parkinson's disease

Indexed keywords

2 (3,4 DIMETHOXYPHENYL) 3 FLUOROALLYLAMINE; ALMOXATONE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CLORGYLINE; DOPAMINE; HARMALINE; KYNURAMINE; MOCLOBEMIDE; MONOAMINE; N (2 PROPYNYL) 1 INDANAMINE; N [2 (2 CHLOROPHENOXY)ETHYL]CYCLOPROPYLAMINE; RADIOISOTOPE; SELEGILINE; SEROTONIN; TRANYLCYPROMINE;

AMINE OXIDASE (FLAVIN CONTAINING) ACTIVITY; AUTOPSY; BRAIN; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DOPAMINE C 14; DRUG COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; ETIOLOGY; HUMAN; HUMAN CELL; NERVOUS SYSTEM; PARKINSON DISEASE; PHENETHYLAMINE C 14; PRIORITY JOURNAL; SEROTONIN C 14; THERAPY;

AGED; AMINES; BRAIN; COMPARATIVE STUDY; DOPAMINE; FEMALE; HUMAN; HYDROXYINDOLEACETIC ACID; INDANS; KYNURAMINE; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PHENETHYLAMINES; SELEGILINE; SEROTONIN; SUPPORT, NON-U.S. GOV'T; TISSUE DISTRIBUTION; TRANYLCYPROMINE;

EID: 0022496317     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.1986.tb01747.x     Document Type: Article

References (48)

1. Behavioural hyperactivity in rats treated with selective monoamine oxidase inhibitors and LM 5008, a selective 5‐hydroxytryptamine uptake blocker
2. Brain amine concentrations after monoamine oxidase inhibitor administration
3. The potentiation of the anti‐akinetic effect of L‐dopa treatment by an inhibitor of MAO‐B, l‐deprenyl
4. Implications of combined treatment with Madopar and l‐deprenil in Parkinson's disease
5. (—)‐Deprenyl leads to prolongation of L‐dopa efficacy in Parkinson's disease
6. Increased life expectancy resulting from addition of L‐deprenyl to Mapodar treatment in Parkinson's disease. A long‐term study
7. A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
8. Multiple forms of human brain mitochondrial monoamine oxidase
9. Rapid method for the determination of 5‐hydroxytryptamine and 5‐hydroxyindole‐acetic acid in small regions of rat brain
10. Chronic Parkinsonism secondary to intravenous injection of mepidrine analogues
11. Deprenyl administration in man: a selective monoamine oxidase inhibitor without the cheese effect
12. Determination of catecholamines in rat brain parts by reversed‐phase ion pair liquid chromatography
13. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors type A and B in the cat
14. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B
15. The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimaxatone
16. Deamination of 5‐hydroxytryptamine by both forms of monoamine oxidase in the rat brain
17. Differences in the preferential deamination of L‐norepinephrine, dopamine, and serotonin by MAO in rodent and primate brain
18. Dopamine is a monoamine oxidase‐B substrate in man
19. Dopamine oxidation and its inhibition by (—)‐deprenyl
20. Effect of monoamine oxidase inhibition by clorgyline, deprenyl or tranylcrypromine on 5‐HT concentration in rat brain and hyperactivity following subsequent tryptophan administration
21. Evidence that dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of enzyme inhibition necessary to increase functional activity of dopamine and 5‐hydroxytryptamine
22. Release of endogenous dopamine from rat isolated striatum: effect of clorgyline and (—)‐deprenyl
23. Protection against the dopaminergic neurotoxicity of I‐methyl‐4‐phenyl 1,2,3,6‐tetrahydropyridine by monoamine oxidase inhibitors
24. Some observation upon a new inhibitor of monoamine oxidase in brain tissue
25. Selective acetylenic suicide and reversible inhibitors of monoamine oxidase type A and B
26. Some puzzling effects of monoamine oxidase inhibitors
27. A rapid microfluorometric determination of monoamine oxidase
28. Chronic Parkinsonism in humans due to a product of meperidine‐analog synthesis
29. Pargyline prevents MPTP‐induced Parkinsonism in primates
30. Deprenyl in Parkinson's disease
31. Protein measurement with the Folin phenol reagent
32. The deamination of dopamine by human brain monoamine oxidase specificity for the two forms in seven brain regions
33. Interneuronal generation of a pyridinium ion metabolite may cause drug‐induced Parkinsonism
34. Amphetamine and phenylethylamine in post‐mortem Parkinson's brain after (—) deprenyl administration
35. On the mode of action of l‐deprenyl in human central nervous system
36. Localization of MAO A and B in human brain: a step in understanding the therapeutic action of l‐deprenyl
37. A new approach to the treatment of Parkinson's disease
38. Deamination of dopamine and its 3‐O‐methylated derivative by human brain monoamine oxidase
39. Assay of monoamine oxidase
40. Allotropic properties of human brain monoamine oxidase
41. The nature and location of the multiple forms of monoamine oxidase
42. Overview of present treatment of Parkinson's disease
43. β‐Phenylethylamine: a specific substrate for type B monoamine oxidase in brain
44. The monoamine oxidase of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines
45. Monoamine oxidase inhibitor antidepressants
46. Monoamine oxidase inhibitor antidepressants
47. Human brain monoamine oxidase: multiple forms and selective inhibition
48. Monoamine oxidase type B inhibitors in human and animal Parkinsonism